| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Fallopian Tube Cancer | |||||
| Ovarian Cancer | |||||
| Peritoneal Cavity Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Fallopian Tube Neoplasms | |||||
| Ovarian Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adnexal Diseases | |||||
| Endocrine Gland Neoplasms | |||||
| Endocrine System Diseases | |||||
| Fallopian Tube Diseases | |||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Gonadal Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Ovarian Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| etoposide | |||||
| topotecan hydrochloride | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Etoposide phosphate | |||||
| Topotecan | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Gynecologic Oncology Group | |||||
| National Cancer Institute (NCI) | |||||
|
